Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $24.00 price objective on the biotechnology company’s stock.

A number of other research analysts also recently commented on AVXL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Anavex Life Sciences Stock Up 8.9%

AVXL stock opened at $3.07 on Tuesday. The business has a 50 day moving average price of $4.30 and a 200 day moving average price of $5.50. The stock has a market cap of $284.50 million, a price-to-earnings ratio of -6.67 and a beta of 1.08. Anavex Life Sciences has a fifty-two week low of $2.61 and a fifty-two week high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04. As a group, sell-side analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC purchased a new stake in shares of Anavex Life Sciences in the fourth quarter valued at about $104,000. NewEdge Advisors LLC grew its holdings in shares of Anavex Life Sciences by 1,636.2% during the fourth quarter. NewEdge Advisors LLC now owns 28,231 shares of the biotechnology company’s stock worth $101,000 after buying an additional 26,605 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Anavex Life Sciences by 21.2% during the fourth quarter. XTX Topco Ltd now owns 99,058 shares of the biotechnology company’s stock worth $353,000 after buying an additional 17,356 shares during the last quarter. Man Group plc increased its position in Anavex Life Sciences by 126.5% in the 4th quarter. Man Group plc now owns 55,223 shares of the biotechnology company’s stock valued at $197,000 after acquiring an additional 30,838 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Anavex Life Sciences in the 4th quarter valued at about $164,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.